Stocks › NVO

Novo-Nordisk A/S NVO

US equityMarket cap rank #89

$38.41

+$0.24 (+0.63%)

Market open · Sep 24, 1:10 pm ET

After hours $38.21 +0.11%

Open$37.97

Prev close$38.17

Day range$37.92 – $38.72

Volume12.40M

Market cap$171.50B

P/E (TTM)9.6

Dividend yield4.64%

Morgan Stanley Downgrades Novo-Nordisk A/S(NVO.US) to Sell Rating, Maintains Target Price $40 Market news · 11 Sep 2026
Eli Lilly and Co (LLY.US) and Novo-Nordisk A/S (NVO.US) win GLP-1 antitrust lawsuit as U.S. court dismisses allegations by rival pharmacy Zhitong Finance · 7 Aug 2026
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Raises Target Price to $47 Market news · 6 Aug 2026
Novo-Nordisk A/S (NVO.US) Q2 earnings beat expectations and full-year guidance was raised, yet underlying concerns persist! Weak sales of oral Wegovy cast a shadow over its path back to growth. Zhitong Finance · 5 Aug 2026
Analysts' Opinions Are Mixed on These Healthcare Stocks: BrightSpring Health Services, Inc. (BTSG), AbbVie (ABBV) and Novo Nordisk (NVO) TipRanks · 3 Aug 2026
Novo-Nordisk A/S (NVO.US) has submitted a marketing application in China for Wegovy tablets for long-term weight management. Zhitong Finance · 27 Aug 2026
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Maintains Target Price $47 Market news · 18 Aug 2026
Goldman Sachs Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Raises Target Price to $47 Market news · 3 Jun 2026
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Maintains Target Price $45 Market news · 22 Jun 2026
Berenberg Bank Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Cuts Target Price to $47 Market news · 12 Mar 2026
TD Cowen Downgrades Novo-Nordisk A/S(NVO.US) to Hold Rating, Cuts Target Price to $42 Market news · 10 Mar 2026